Welcome to our dedicated page for CURANEX PHARMACEUTICALS news (Ticker: CURX), a resource for investors and traders seeking the latest updates and insights on CURANEX PHARMACEUTICALS stock.
Curanex Pharmaceuticals Inc. develops botanical drug candidates for serious diseases with unmet medical need. Company news centers on Phyto-N, its lead botanical therapeutic candidate, including preclinical toxicology work, IND preparation, pharmacokinetics and Chemistry, Manufacturing and Controls activities tied to inflammatory-disease development.
Recurring updates also cover the company’s expanded focus on cancer cachexia and advanced cancer supportive care, alongside its broader pipeline references to ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease and gout. Other company developments include patient case reports, Scientific Advisory Board activity, capital-structure disclosures, governance matters, operating results and Nasdaq listing-compliance communications.
Curanex (Nasdaq: CURX) reported first quarter 2026 progress on lead candidate Phyto-N for ulcerative colitis and outlined a planned Q4 2026 IND submission to the FDA.
The company completed GMP pilot-scale manufacturing, a 28-day dose-range finding toxicology study with no treatment-related toxicological findings, expanded its pipeline to cancer cachexia, and reported $4.0 million in cash and equivalents as of March 31, 2026.
Curanex (Nasdaq: CURX) highlighted five additional patient case reports dated April 8, 2026, describing rapid improvements in appetite, mobility, organ function, and quality of life after taking the company's product.
Cases span advanced thymic carcinoma, small cell lung cancer, pancreatic post‑surgical multi‑organ failure, end‑stage liver cirrhosis, and end‑stage renal disease, with reported weight gain (~17 lb), tumor shrinkage, restored urination, and discharge from hospital in days to weeks.
Curanex (Nasdaq: CURX) highlighted a single-patient case suggesting Phyto-N may relieve symptoms linked to cancer cachexia and advanced supportive care. The patient reported meaningful symptomatic improvement within ~1 month and sustained functional ability for over two years; lab markers (amylase, lipase, triglycerides) normalized over ~3 months.
The company cautions this is a single case and does not establish safety or efficacy, while Phyto-N remains in preclinical development with an IND planned for ulcerative colitis.
Curanex (NASDAQ: CURX) is expanding its development pipeline to add cancer cachexia as a new core indication, citing a large unmet need and commercial opportunity. The company notes the global market was about $2.54 billion in 2024, projected to $3.90 billion by 2033, and plans to evaluate development paths while advancing lead program Phyto-N.
Curanex (Nasdaq: CURX) provided a business update alongside its 2025 Form 10-K, reporting operational progress toward a planned IND submission for Phyto-N in Q4 2026. The company completed a pilot-scale GMP batch, finished dose-range finding toxicology in rats and dogs, filed a PCT application in March 2025, and says it has funding for at least twelve months to support near-term IND-enabling activities.
Curanex (Nasdaq: CURX) completed a 28-day repeat-dose dose-range finding toxicology study of lead botanical candidate Phyto-N in rats and dogs, finding no toxicological findings at the maximum feasible dose. The highest dose equated to ~6x the proposed clinical dose in dogs and ~4x in rats.
The MFD will anchor pivotal GLP toxicology studies required for a planned IND submission targeted for Q4 2026. Phyto-N has >30 years of prior human use in China.
Curanex (NASDAQ: CURX) appointed Dr. Taku Kambayashi and Dr. Selvakumar Subbian to its Scientific Advisory Board to support immunology, infectious disease research, IND preparation and intellectual property strategy. The company said it will name one additional advisor pending employer approval.
Curanex targets completion of FDA-required preclinical studies and an IND submission with clinical trials planned for Q4 2026.
Curanex (Nasdaq: CURX) appointed Dr. Daniel Pascheles and Dr. Nicholas A. Meanwell to its Scientific Advisory Board on March 11, 2026. The advisors bring a combined >75 years of pharmaceutical experience and will advise on commercial strategy, product portfolio development, and go‑to‑market decisions.
Dr. Pascheles previously led global competitive intelligence at Merck and held senior roles at Aventis; Dr. Meanwell led drug discovery at Bristol Myers Squibb and advanced 33 clinical candidates, including multiple approved medicines.
Curanex (NASDAQ: CURX) announced formation of a five-member Scientific Advisory Board on March 5, 2026 to support R&D, upcoming clinical trials, technical development, intellectual property, commercialization and strategic value creation.
The board will include two industry commercial experts and three academic researchers; full member names will be disclosed shortly.
Curanex (Nasdaq: CURX) completed a GMP-compliant pilot-scale batch of its lead botanical candidate Phyto-N, advancing CMC readiness to support GLP toxicology, pharmacokinetic, and other IND-enabling studies. The company continues to target an IND submission for ulcerative colitis in Q4 2026.
Completed CMC activities include QC methods for raw materials, lab-scale process optimization, and GMP pilot production; non-GLP safety and metabolism studies showed no treatment-related toxicity and minimal interspecies variability.